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The presence of disseminated tumour cells in the bone marrow
is inversely related to circulating free DNA in plasma in
breast cancer dormancy
RE Payne1, NL Hava1, K Page2, K Blighe2, B Ward3, M Slade1, J Brown2, DS Guttery2, SAA Zaidi1, J Stebbing1,
J Jacob1, E Yagu¨e1, JA Shaw2 and RC Coombes*,1
1Division of Cancer, Imperial College, MRC Cyclotron Building, Imperial College Healthcare NHS Trust, Hammersmith Hospital, Du Cane Road,
London W12 ONN, UK; 2Department of Cancer Studies and Molecular Medicine, University of Leicester, Robert Kilpatrick Building, PO Box 65,
Leicester Royal Inf irmary, Leicester LE2 7LX, UK; 3Department of Medical Oncology, Charing Cross Hospital, London W6 8RF, UK
BACKGROUND: The aim of this study was to gain insight into breast cancer dormancy by examining different measures of minimal
residual disease (MRD) over time in relation to known prognostic factors.
METHODS: Sixty-four primary breast cancer patients on follow-up (a median of 8.3 years post surgery) who were disease free had
sequential bone marrow aspirates and blood samples taken for the measurement of disseminated tumour cells (DTCs), circulating
tumour cells (CTCs) by CellSearch and qPCR measurement of overlapping (96-bp and 291-bp) amplicons in circulating free DNA
(cfDNA).
RESULTS: The presence of CTCs was correlated with the presence of DTCs measured by immunocytochemistry (P¼ 0.01) but both
were infrequently detected. Increasing cfDNA concentration correlated with ER, HER2 and triple-negative tumours and high tumour
grade, and the 291-bp amplicon was inversely correlated with DTCs measured by CK19 qRT-PCR (P¼ 0.047).
CONCLUSION: Our results show that breast cancer patients have evidence of MRD for many years after diagnosis despite there being
no overt evidence of disease. The inverse relationship between bone marrow CK19 mRNA and the 291-bp amplicon in cfDNA
suggests that an inverse relationship between a measure of cell viability in the bone marrow (DTCs) and cell death in the plasma
occurs during the dormancy phase of breast cancer.
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Patients with primary breast cancer frequently have evidence of
minimal residual disease (MRD) in the absence of any clinical or
radiological evidence of metastases (Slade et al, 2009). The
detection of circulating tumour cells (CTCs) in the blood and
disseminated tumour cells (DTCs) in the bone marrow of disease-
free patients with breast cancer has been well documented. Their
presence identifies those patients with a worse prognosis, although
many remain disease free for many years or decades (Meng et al,
2004; Braun et al, 2005; Slade et al, 2009). In addition, circulating
free DNA (cfDNA) has been found in higher concentrations in
cancer patients than healthy controls and has been proven to share
similar genetic features to the primary tumour (Leon et al, 1977;
Stroun et al, 1989). Larger fragment sizes of cfDNA, greater than
the apoptotic limit, have also been detected in the blood of cancer
patients; believed to be derived from tumour cell necrosis and lysis
(Jahr et al, 2001; Wang et al, 2003; Umetani et al, 2006). The
relationship of these measures of MRD to long-term breast cancer
dormancy has not been fully established.
Many post-operative studies have principally been carried out
by sampling patients’ bone marrow or blood shortly after surgery
or adjuvant chemotherapy during the period of highest risk
of relapse; however, very few studies have focused on the later
‘low risk’ period, that is, later than 4 years after surgery. Patients in
this period with MRD present are likely to have cells in a dormant
state although the precise mechanisms are unclear. We decided to
concentrate on this period for several reasons. First, a proportion
of patients relapse during this period: it is generally agreed that
there is a constant rate of relapse of around 1–2% annually
(van der Sangen et al, 2011); many patients develop evidence of
widespread metastatic disease in intervals between clinic visits,
and this is a considerable cause of morbidity. Second, we reasoned
that if a test, or combination of tests, could be shown to indicate
recurrent disease during this time, this may provide a reason to
instigate systemic therapy at an earlier stage, with the aim of
eradicating the disease. Finally, it was possible that we would find a
subset of patients who had no evidence of disease at any time point
using any test; these patients should not need to be followed up in
clinic, thus reducing patient anxiety and cost.
The phenomenon of ‘dormancy’ in relation to cancer has been
extensively described in the literature (Meng et al, 2004; Almog
et al, 2009; Willis et al, 2010). The exact mechanisms of dormancy
are still not clearly understood; however, evidence of a relationship
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between tumour dormancy and increased apoptosis exists. In a
mouse model under angiogenic suppression, tumour cell pro-
liferation was balanced by a reciprocal amount of cell death
(Holmgren et al, 1995). We hypothesised that by combining tests
indicating cell death (cfDNA) with other measures of viability
(DTC and CTC detection), we could determine the relationship
between the two processes.
The comparison of cfDNA with other markers of MRD has not
been fully assessed, although evidence for a positive association of
cfDNA with viable CTCs detected by an epithelial immunospot
assay has been described (Schwarzenbach et al, 2009a).
Conversely, no correlation of cfDNA with DTCs measured by
immunocytochemistry (ICC) was found (Schwarzenbach et al,
2009b). In this study, we aimed to find a combination of tests to
characterise dormancy mechanisms in breast cancer patients,
which would enable possible routes of therapeutic intervention.
For this, we compared DTCs measured by two methods
(quantitative RT-PCR measurement of cytokeratin 19 (CK19) and
ICC, using a pan-cytokeratin antibody) and CTCs by CellSearch
with two measures of cfDNA. The tests consisted of the
measurement of two overlapping amplicons: a 96-bp amplicon,
representing total cfDNA and a larger 291-bp amplicon that was
above the apoptotic limit (185–200-bp) and believed to be mostly
cancer associated. These measurements of MRD were compared
with each other and with prognostic factors in patients with breast
cancer on long-term follow-up.
MATERIALS AND METHODS
Primary breast cancer patients and control groups
Three control groups were recruited to measure CTCs and cfDNA
in the blood; these consisted of 34 healthy female controls (29 of
which had CTCs measured) and 51 patients with benign breast
disease (BBD; 28 of which had CTCs measured). Thirty-one
patients with metastatic breast cancer were used as a control group
to confirm raised levels of cfDNA and a higher number of CTCs
(eight of these patients had CTCs measured) as compared with
healthy controls (Allard et al, 2004; Van der Auwera et al, 2009).
All patient groups including the primary breast cancer patients
signed a written consent form; both form and protocol had been
approved by the local ethics committee (RREC numbers 0975).
Disseminated tumour cells in the bone marrow were not measured
in the control groups for ethical reasons, but our test for bone
marrow DTCs has been standardised and extensively validated in
previous studies (Borgen et al, 1999; Slade et al, 1999, 2005, 2009).
The amount of blood taken for CTC measurement was 22.5ml in
the healthy controls and patients with BBD and 7.5ml in the
patients with metastatic breast cancer. Twenty millilitres of blood
was taken for all cfDNA analyses.
In this study, we recruited 64 patients who had been treated
for primary breast cancer. Twenty-two patients had previously
been recruited to our MRD studies (Slade et al, 2005, 2009).
Twenty-nine patients were recruited from a trial of adjuvant high-
dose chemotherapy (Coombes et al, 2005) and were selected
because they had a high risk of relapse. The remaining 13 patients
were selected as additional patients for statistical purposes. The
inclusion criteria included a histologically confirmed breast
cancer and consent to the follow-up procedure (see below).
Exclusion criteria included evidence of recurrent disease on
conventional staging with isotopic bone scan and computed
tomography of the chest and liver/abdomen, before study entry.
All patients agreed to repeat bone marrow sampling at the outset
of the study followed by repeat blood sampling for further tests to
measure MRD. In all, 43 (67%) patients received adjuvant
chemotherapy and 58 (91%) patients received adjuvant endocrine
therapy (Table 1).
Detection of CTCs and DTCs from blood and
bone marrow
The skin was incised before the bone marrow aspirates were taken
to minimise the risk of epithelial contamination. Between 2 and
5ml of bone marrow was aspirated into syringes primed with
preservative-free heparin (Leo Labs, Risborough, UK). Cells were
cytocentrifuged at a concentration of 5 105 per cytospin; air-
dried and stored at 20 1C before use. Slides were then stained for
a common epitope of cytokeratin as previously described (Pantel
et al, 1994; Slade et al, 1999; Smith et al, 2000). Samples that were
isotype positive were deemed uninterpretable and therefore
excluded from the results. The MCF-7 cell line was used as a
positive control. Real-time qRT-PCR for CK19 and ABLmRNA was
performed as described previously (Slade et al, 2005). The
standard used for quantification was the artificial construct in
the range 101–104 for CK19 and 103–106 for ABL per 2.5 ml (Slade
et al, 1999). All assays were performed with duplicate standards, a
non-cDNA control and a positive cDNA control were extracted
from the MCF-7 cell line. A CK19:ABL ratio greater or equal to
Table 1 Primary breast cancer patient characteristics
Lymph
node-
positive
patients (%)
Lymph
node-
negative
patients (%) Total (%)
Menopausal status
Pre-menopausal 11 26 7 32 18 28
Post-menopausal 31 74 15 68 46 72
Histology
Invasive ductal 31 74 16 73 47 73
Invasive lobular 7 17 2 9 9 14
Other/mixed invasive 4 9 4 18 8 13
Tumour size
T1 15 36 20 91 35 55
T2 16 38 2 9 18 28
T3 7 17 0 0 7 11
T4 0 0 0 0 0 0
Unknown 4 9 0 0 4 6
Tumour grade
I 1 2 5 23 6 9
II 20 48 9 41 29 45
III 20 48 8 36 28 44
Unknown 1 2 0 0 1 2
Hormone receptor status
ER positive 29 69 17 77 46 72
ER negative 10 24 5 9 15 23
Unknown ER status 3 7 0 0 3 5
PgR positive 17 40 13 59 30 47
PgR negative 19 45 7 32 26 41
Unknown PgR status 6 14 2 9 8 12
HER2 status
Positive 13 31 3 14 16 25
Negative 26 62 17 77 43 67
Unknown 3 7 2 9 5 8
Endocrine therapy
Yes 41 98 17 77 58 91
No 1 2 5 23 6 9
Chemotherapy
Yes 35 83 8 36 43 67
No 7 17 14 64 21 33
Total number of patients 42 66 22 34 64 100
Abbreviations: ER¼ oestrogen receptor; PgR¼ progesterone receptor.
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0.1% (one CK19/1000 ABL transcripts) was regarded as positive. All
samples were anonymised to the person performing the assays. For
the detection of CTCs, 7.5ml of blood from the metastatic patients
and 3 7.5ml from the control and primary breast cancer patients,
were collected in CellSave preservative tubes (Veridex, LLC, Warren,
NJ, USA) from patients in London, anonymised and transported at
room temperature to the Department of Surgery and Cancer,
Imperial College London for processing within 72h of collection as
recommended by the manufacturer. The CellSearch System
(Veridex, LLC, Warren, NJ, USA) was used for the isolation and
enumeration of CTCs from each 7.5ml of blood separately using
specific morphological criteria to identify CTCs (Allard et al, 2004).
CfDNA detection and analysis
Blood samples were collected in EDTA tubes and processed within
3 h of venesection. Plasma was separated by centrifugation at
1200 g for 10min, and plasma was taken from the upper phase and
decanted into fresh polypropylene tubes. Tubes were then spun
again to remove any contaminating leucocytes (Chiu et al, 2001),
and the resulting supernatant was aliquoted into sterile tubes and
stored at 80 1C. Plasma samples were allowed to thaw to room
temperature and re-spun in a bench-top centrifuge to remove any
remaining cell debris as recommended (Page et al, 2006), and
cfDNA was isolated as described previously (Page et al, 2011).
To estimate cfDNA quantity, the concentration of a 96-bp GAPDH
amplicon served as a measure of total cfDNA quantity, whereas a
larger overlapping 291-bp amplicon measured total cfDNA above the
limit of apoptosis. The integrity of cfDNA was calculated as a ratio of
the 96-bp and 291-bp amplicons (291-bp/(291-bpþ 96-bp)). Primers
and conditions are as described previously (Page et al, 2011).
Study design
The primary objective of this prospective, longitudinal study was
to investigate the natural history of DTCs in bone marrow
aspirates from 64 primary breast cancer patients. This study also
had secondary objectives to investigate the presence and quantity
of CTCs and cfDNA in blood. Few patients relapsed with recurrent
Table 2 CTC measurements from blood and cell-free DNA quantity in
plasma are lower in healthy controls and benign breast disease patients
than in metastatic breast cancer
Healthy
controls
Benign
breast
disease
patients
Metastatic
breast
cancer
patients
Cell-free DNA 96-bp (ngml1)
No. of patients 34 51 31
Mean 0.24 0.54 3.5
95% Confidence interval 0.09–0.63 0.27–1.07 1.48–8.29
Median 0.86 1.27 2.45
Range 0–4.52 0–8.36 0.03–1044
Cell-free DNA 291-bp (ngml1)
No. of patients 34 51 31
Mean 0.24 0.44 3.5
95% Confidence interval 0–0.20 0.1–0.40 0–1.5
Median 0 0.22 0.44
Range 0–1.37 0–1.94 0–602
Cell-free DNA integritya
No. of patients 34 51 31
Mean 0.10 0.28 0.21
95% Confidence interval 0–0.13 0.11–0.25 0–0.34
Median 0 0.2 0.07
Range 0–0.39 0–0.49 0–0.83
Circulating tumour cellsb
No. of patients 29 28 8
Volume of blood measured 22.5ml 22.5ml 7.5ml
Mean 0.03 0.29 24
95% Confidence interval 0.04–0.11 0.09–0.66 7.29–55.29
Median 0 0 9
Range 0–1 0–5 0–109
No. of patients with CTCsc 1 (3%) 4 (14%) 6 (75%)
Abbreviation: CTC¼ circulating tumour cell. aCalculated as the ratio of the 96-bp and
291-bp amplicons (291-bp/(291-bp+96-bp)). bDetected with the CellSearch system.
cSamples were considered positive for CTCs when at least one cell was detected per
total sample volume.
Table 3 Minimal residual disease marker values in lymph node-positive
and lymph node-negative primary breast cancer patients in samples taken
over time
Lymph
node-positive
patients at
surgery
(n¼ 42)
Lymph
node-negative
patients at
surgery
(n¼ 22) P-value
Cell-free DNA 96-bp (ngml1)
Mean 19.19 14.19 o0.0001a
95% CI 0.61–18.93 0.24–7.52
Median 1.06 3.01
Range 0–2626 0–440
No. of samples 323 152
Cell-free DNA 291-bp (ngml1)
Mean 4.35 2.66 0.0248a
95% CI 0.16–4.90 0.05–1.43
Median 0.17 0.38
Range 0–785 0–78
No. of samples 322 149
Cell-free DNA integrityb
Mean 0.22 0.18 0.479
95% CI 0.001–0.029 0.001–0.037
Median 0.17 0.13
Range 0–1 0–1
No. of samples 257 136
Disseminated tumour cells (qRT-PCR)c
Mean 0.09 0.07 0.0154a
95% CI 0–0.012 0.001–0.023
Median 0.053 0.04
Range 0–1.25 0–1.12
No. of samples 475 133
Disseminated tumour cells (ICC)d
Mean 0.94 0.79 0.063
0.005–0.15 0.009–0.28
Median 0 0
Range 0–15 0–12
No. of samples 463 139
Circulating tumour cellse,f
Mean 0.55 0.15 0.982
0.012–0.389 0.003–0.099
Median 0 0
Range 0–23 0–2
No. of samples 153 72
Abbreviations: CI¼ confidence interval; ICC¼ immunocytochemistry; qRT-
PCR¼ quantitative reverse transcription-PCR. aStatistically significant, Mann–Whit-
ney t-test. bCalculated as the ratio of the 96- and 291-bp amplicons (291-bp/(291-
bp+96-bp). cCalculated as the percentage ratio of qRT-PCR CK19:ABL. dDetected
by pan-CK antibody. eSamples were considered positive for circulating tumour cells
when at least one cell was detected in 22.5ml of blood. fDetected with the
CellSearch system.
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disease therefore MRD values were compared with each other and
with prognostic factors in a univariate analysis. For ethical and
technical reasons, samples measuring CTCs and cfDNA were taken
at fewer time points as detailed below.
Statistical methods
The main continuous variables of 96- and 291-bp amplicons in
cfDNA, ICC and qRT-PCR assays for DTC, and CTC assay were
positively skewed. The Spearman rank correlation (corrected
for ties) was used to assess monotonic relationships between
continuous variables. The Mann–Whitney test was used to
compare continuous scores between two groups. One-way analysis
of variance was used to compare more than two groups. A binary
DTC qRT-PCR outcome was defined (o0.1% is a negative result
and X0.1% is a positive result).
RESULTS
Patients and sampling
Sixty-four disease-free patients with a diagnosis of primary breast
cancer were followed up for 1–11.5 years after surgery (a median
of 8.3 years). In terms of their primary staging, 20 patients had
tumours measuring o20mm with no involved lymph nodes
detected (T1N0), 4 patients had 1–3 involved lymph nodes
detected, 2 patients had tumours measuring 420mm with no
involved lymph nodes detected and 38 high-risk patients had 43
involved lymph nodes at surgery. For the purposes of this study,
patients were grouped into node-positive (n¼ 42) or node-
negative (n¼ 22) groups (Table 1). Table 1 also shows patient
characteristics and adjuvant systemic therapy details. The node-
positive patients had bone marrow aspirates taken every 6 months,
and node-negative patients every 12 months for ethical reasons.
Blood samples were obtained 3–6 monthly post-operatively over a
follow-up period of up to 11.5 years. For cfDNA, 2–13 (a mean of
7.4) plasma samples were analysed per patient and 0–7 (a mean
of 3.5) samples for CTC analysis using the CellSearch system. For
DTC analysis, 0–21 (a mean of 9.5) bone marrow aspirates were
taken from each patient (both ICC and qRT-PCR if the volume was
sufficient). A total of 168 bone marrow aspirates were taken at the
same time points as the blood sampling and used in the direct
comparison of DTCs, CTCs and cfDNA. All samples for CTC
analysis also had corresponding samples for cfDNA analysis.
Total measurements of DTCs, CTCs and cfDNA were used when
comparing values from lymph node positive with lymph node-
negative breast cancer patients.
Minimal residual disease measurements in control groups
Only 1 of 29 (3%) healthy female controls had a single CTC
detected and 4 of 28 (14%) patients with BBD had CTCs present in
Table 4 Comparison of minimal residual disease markers in primary breast cancer patients with hormone receptor and HER2 receptor status of the
primary tumour
ER status HER2 status PR status Triple negative status
Positive Negative Positive Negative Positive Negative Yes No
Total circulating free DNA 96-bp (ngml1)
No. of samples 341 105 128 308 220 187 81 364
Mean 21.67 4.82 21.2 15.14 9.50 30.23 5.29 20.43
95% CI 3.42 to 39.92 3.14 to 6.51 4.81 to 47.2 1.81 to 32.10 4.11 to 14.9 2.54 to 63 3.15 to 7.43 3.34 to 37.53
Median 1.2 2.29 0.89 1.91 1.70 1.35 2.49 1.21
Range 0 – 2626 0–53.71 0 – 1581 0–2626 0–440 0–2626 0–53.71 0 – 2626
P-value 0.004a 0.013a 0.71 0.004a
Circulating free DNA 291-bp (ngml1)
No. of samples 336 106 129 305 215 188 82 360
Mean 4.46 4.46 8.08 1.79 2.08 6.85 2.84 4.21
95% CI 0.28 to 9.20 0.79 to 3.87 4.11 to 20.28 1.01 to 2.57 0.68 to 3.47 1.53 to 15.22 0.86 to 4.83 0.22 to 8.63
Median 0.23 0.19 0.1 0.28 0.38 0.16 0.24 0.23
Range 0 – 785.4 0 – 56 0–785.4 0 – 78.03 0 – 124 0–785 0–56 0–785.4
P-value 0.792 0.188 0.23 0.50
Disseminated tumour cells (qRT-PCR)b
No. of samples 440 135 171 399 273 261 106 476
Mean 0.087 0.096 0.87 0.09 0.07 0.10 0.09 0.089
95% CI 0.07 – 0.10 0.07 – 0.11 0.07 – 0.11 0.08 – 0.10 0.06 – 0.09 0.08 – 0.12 0.07 – 0.11 0.08 – 0.10
Median 0.05 0.07 0.05 0.048 0.05 0.05 0.08 0.05
Range 0 – 1.25 0 – 0.79 0 – 0.79 0 – 1.25 0 – 1.12 0 – 1.25 0 – 0.65 0 – 1.25
P-value 0.11 0.39 0.02a 0.06
Disseminated tumour cells (ICC)c
No. of samples 136 435 175 389 272 260 102 474
Mean 1.02 0.86 0.82 0.93 0.81 0.98 1.15 0.88
95% CI 0.67 – 1.36 0.72 – 1.00 0.60 – 1.03 0.75 – 1.11 1.47 1.82 0.70 – 1.60 0.74 – 1.02
Median 0 0 0 0 0 0 0 0
Range 0 – 15 0–12 0–9 0–15 0–12 0–15 0 –15 0–12
P-value 0.34 0.45 0.23 0.16
Circulating tumour cellsd
No. of samples 166 48 74 135 125 72 34 178
Mean 0.36 0.67 0.54 0.38 0.40 0.51 0.91 0.34
95% CI 0.08 to 0.64 0.15 to 1.49 0.09 to 1.17 0.08 to 0.67 0.03 to 0.77 0.03 to 1.06 0.25 to 2.08 0.08 to 0.61
Median 0 0 0 0 0 0 0 0
Range 0 – 23 0–19 0–23 0–19 0–23 0–19 0–19 0–23
P-value 0.38 0.60 0.73 0.15
Abbreviations: CI¼ confidence interval; ICC¼ immunocytochemistry; qRT-PCR¼ quantitative reverse transcription-PCR. aStatistically significant difference of median values by
Mann–Whitney test or mean values by t-test. bCalculated as the percentage ratio of qRT-PCR CK19:ABL (X0.1 is considered positive). cDetected by pan-CK antibody. dSamples
were considered positive for circulating tumour cells when at least one cell was detected in 22.5ml of blood by the CellSearch system.
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22.5ml of blood; 1 CTC was present in 3 patients and 5 CTCs were
present in 1 patient. For comparative purposes, CTCs were also
measured in patients with metastatic breast cancer and were
present in six of eight (75%) patients (range 0–109). The quantity
of both the 96- and 291-bp amplicons in cfDNA was lower in the
healthy controls (n¼ 34) and women with BBD (n¼ 51) than in
patients with metastatic breast cancer. The mean cfDNA value of
the mostly cancer-associated 291-bp amplicon was 0.24 ngml1 in
the healthy controls and 0.44 ngml1 in the BBD patients
compared with 3.5 ngml1 in the patients with metastatic breast
cancer (P¼ 0.032; Table 2). The mean levels of the 291-bp cfDNA
in patients with primary breast cancer were also higher than in
healthy or BBD controls (3.8 ngml1). This was similar to the
mean level in the metastatic patient group. Patients with primary
breast cancer also showed a higher mean number of CTCs per
sample compared with healthy and BBD controls (0.42 compared
with 0.03 and 0.29 CTCs, respectively; Tables 2 and 3).
Comparisons of markers of MRD with established
prognostic factors in 64 breast cancer patients on
long-term follow-up
Samples from multiple time points taken from each of the 64
primary breast cancer patients on long-term follow-up were
included in this pooled analysis. In all, 8 of the 64 patients
relapsed. There were no significant differences in cfDNA
concentration, cfDNA integrity, DTC ICC or CTCs in the eight
patients who had relapsed compared with the 56 who had not.
However, there was a significant difference in the level of DTC
detection in BM by qRT-PCR (P¼ 0.025, Mann–Whitney). Next,
we compared measures of MRD in all 64 patients, comparing
lymph node-negative vs lymph node-positive patients. The mean
quantities of both the 96- and 291-bp amplicons in cfDNA were
correlated with the number of lymph nodes positive at surgery
(Po0.0001 and P¼ 0.0248, respectively; Table 3). However, there
was extensive overlap in the value ranges between node-positive
and node-negative patients (Supplementary Figure 1). Dissemi-
nated tumour cells (qRT-PCR) in the BM were positively correlated
with node-positive patients (P¼ 0.0154). There was no association
between DTCs (ICC) or CTCs and node status. The measures of
MRD (DTCs, CTCs and cfDNA) from individual blood or bone
marrow samples were also compared with conventional prognostic
factors in the 64 patients. In cfDNA, the 96-bp amplicon was
significantly higher in patients with ER-negative (P¼ 0.004),
HER2-negative (P¼ 0.013) and triple-negative status (P¼ 0.004)
compared with those whose tumours express ER or HER2. The
DTC (qRT-PCR) median values were also higher in PR-negative
patients (P¼ 0.02) and triple-negative patients but this did not
reach statistical significance (P¼ 0.06; Table 4).
When considering tumour size, grade and menopausal status,
there were three significant associations: the 96-bp cfDNA
amplicon was significantly higher in patients with high-grade
Table 5 Comparison of minimal residual disease markers in primary breast cancer patients with menopausal status and with tumour size and grade of the
primary tumour
Menopausal status Tumour size Grade
Post Pre T1 T2 T3 1 2 3
Total circulating free DNA 96-bp (ngml1)
Mean 32.61 4.31 8.3 40.99 3.73 13.84 7.26 27.73
95% CI 3.32 to 61.9 2.6 to 6.02 3.85 to 12.74 3.12 to 85.17 1.71 to 5.76 9.53 to 37.21 3.46 to 11.06 0.89 to 56.36
Median 1.72 1.72 1.91 1.01 1.12 0.55 1.27 1.9
Range 0 – 2626 1–197.6 0 – 439.6 0 – 2626 0–45.41 0 – 439.6 0 – 264 0–2626
No. of samples 212 262 254 139 53 38 217 2
P-value 0.120 0.262 0.032a
Circulating free DNA 291-bp (ngml1)
Mean 6.77 1.35 2.38 7.74 0.74 1.47 1.78 5.99
95% CI 0.78 to 14.32 0.71 to 1.2 1.1 to 3.66 3.53 to 19.08 0.2 to 1.29 0.35 to 2.53 0.39 to 3.17 1.31 to 13.3
Median 0.32 0.095 0.4 0.14 0.12 0.03 0.17 0.29
Range 0 – 785.4 0 – 56 0–124.2 0 – 785.4 0 – 13.68 0 – 16.04 0 – 124.2 0 – 785.4
No. of samples 211 260 251 139 52 36 215 215
P-value 0.033a 0.102 0.305
Disseminated tumour cells(qRT-PCR)b
Mean 0.087 0.088 0.08 0.09 0.104 0.08 0.08 0.1
95% CI 0.07 – 0.1 0.07 – 0.1 0.07 – 0.1 0.07 – 0.11 0.07 – 0.14 0.05 – 0.1 0.07 – 0.10 0.08 – 0.11
Median 0.05 0.06 0.05 0.05 0.05 0.04 0.05 0.05
Range 0 – 1.12 0 – 1.25 0 – 1.124 0 –1.02 0 – 1.25 0 – 0.4 0 – 1.25 0 – 1.02
No. of samples 258 358 256 192 113 49 257 290
P-value 0.299 0.846 0.519
Disseminated tumour cells (ICC)c
Mean 0.8 0.97 0.88 0.73 1.12 0.92 0.88 0.93
95% CI 0.62 – 0.97 0.78 – 1.12 0.67 – 1.08 0.56 – 0.89 0.66 – 1.57 0.31 – 1.52 0.69 – 1.07 0.72 – 1.13
Median 0 0 0 0 0 0 0 0
Range 0 – 11 0–15 0–12 0–7 0–15 0–12 0–9 0–15
No. of samples 259 351 259 215 87 47 262 284
P-value 0.307 0.378 0.809
Circulating tumour cellsd
Mean 0.37 0.46 0.17 0.59 1.03 0.35 0.15 0.68
95% CI 0.09 to 0.83 0.14 to 0.79 0.09 to 0.25 0.06 to 1.25 0.34 to 2.4 0.01 to 0.68 0.07 to 0.23 0.12 to 1.24
Median 0 0 0 0 0 0 0 0
Range 0 – 23 0–19 0–2 0–23 0–19 0–3 0–2 0–23
No. of samples 100 125 120 71 29 23 95 107
P-value 0.026a 0.197 0.201
Abbreviations: CI¼ confidence interval; ICC¼ immunocytochemistry; qRT-PCR¼ quantitative reverse transcription-PCR. aStatistically significant by one-way analysis of variance,
Kruskal –Wallis or Mann–Whitney t-test. bCalculated as the percentage ratio of qRT-PCR CK19:ABL (0.1 or more is considered positive). cDetected by pan-CK antibody.
dSamples were considered positive for circulating tumour cells when at least one cell was detected in 22.5ml of blood by the CellSearch system.
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tumours (P¼ 0.032), and the 291-bp cfDNA amplicon (P¼ 0.033)
and the number of CTCs detected (P¼ 0.026) were both higher in
post-menopausal women compared with pre-menopausal women
(Table 5). However, there was extensive overlap in the value ranges
between groups (Supplementary Figure 2).
Relationships between different measures of MRD
In all, 41 out of the 64 patients on follow-up for primary breast
cancer had both DTC and CTC values measured at the same time.
Circulating tumour cells were positively correlated with DTCs
measured by ICC only (P¼ 0.01). This confirms our previous
findings: 16 out of 19 (84%) high-risk primary breast cancer
patients with DTCs present by ICC also had CTCs present (Slade
et al, 2009). However, there was no statistically significant
correlation between CTCs and DTCs measured by CK19
qRT-PCR (Supplementary Table 1).
Next, we investigated the relationship between cfDNA with
DTCs and CTCs by analysing all the matched patient samples with
bone marrow aspirates and blood samples performed at the same
clinic visit or within a month of either sample being taken. A total
of 168 matched bone marrow and blood samples had both DTC
analysis (ICC and qRT-PCR) and qPCR measurement of 96- and
291-bp amplicons in cfDNA. In all, 8 out of 64 patients had no
matched samples; the rest had both a mean and median of 3 per
patient. Up to 179 matched samples were analysed for both CTCs
and cfDNA measuring both 96-bp and 291-bp amplicons.
Interestingly, an inverse correlation was found between the
presence of DTCs as measured by CK19 qRT-PCR and the quantity
of the 291-bp amplicon in cfDNA (P¼ 0.0469) (Figure 1B). The box
plot demonstrates that those patients with DTCs (qRT-PCR) had
lower median and inter-quartile ranges of the 291-bp cfDNA
amplicon than the group with no DTCs present. No other
correlations were evident.
DISCUSSION
Patients with a high risk of relapse based on tumour stage are more
likely to have bone marrow DTCs at presentation (Braun et al,
2005), and these patients are more likely to demonstrate CTCs
during follow-up (Slade et al, 2009). In addition, we and others
have shown that cfDNA is higher in breast cancer patients than
healthy controls (Gal et al, 2004; Huang et al, 2006). It is therefore
important to establish the relationship between the presence of
DTCs, CTCs and cfDNA levels during long-term follow-up.
Our results show that many patients with breast cancer continue
to have evidence of MRD long after the completion of their
adjuvant treatment despite the fact that they have no clinically
evident recurrent disease. Measures of MRD designed to detect
both living and non-viable cells such as CTC/DTC (ICC) and DTC
(qRT-PCR) are intermittently present; their presence does not
appear to indicate inevitable relapse. Higher levels of all MRD
measures were more likely in patients who had an ER-negative,
HER2-negative or triple-negative tumour and who had a higher
grade of tumour although only values for the 96-bp cfDNA
amplicon were significantly higher. Mean quantities of both
amplicons (96 and 291 bp) in cfDNA were correlated with the
number of lymph nodes positive at surgery (Po0.0001 and
P¼ 0.0248, respectively). However, there was extensive overlap in
the value ranges between groups for both cfDNA and the other
measures of MRD suggesting that individual markers have limited
prognostic value in the long-term follow-up of primary breast
cancer patients (Supplementary Figures 1 and 2).
Of interest, cfDNA levels of the larger 291-bp amplicon appear
inversely related to bone marrow dissemination as measured by
qRT-PCR. At first glance, these results appear counter-intuitive.
However, as an increase in larger sized fragments in cfDNA may
result from dying micrometastases, evidence of viable DTCs
as disclosed by an increase in bone marrow CK19 mRNA by
qRT-PCR may be less likely to be found in patients in whom this is
happening. Immunocytochemistry is not a good measure of viable
micrometastases as the method detects both viable and non-viable
cells. For example, a proportion of CTCs detected by the CellSearch
system have expression of a marker of apoptosis indicating they
are not all viable (Rossi et al, 2010). Cells that are viable are also
more likely to have intact mRNA and so may explain why DTCs
and CTCs measured by CK19 mRNA are a better predictive
indicator of prognosis (Smith et al, 2000; Benoy et al, 2006; Farmen
et al, 2008).
Although cfDNA is more informative, in that all blood samples
contain measurable cfDNA, these results suggest that simple
quantification of cfDNA alone is not a useful prognostic marker
during the follow-up period and a panel of MRD markers may be
required. For example, evidence that cfDNA is tumour derived
using genomic technologies may provide more information about
genomic alterations of clinical significance (Shaw et al, 2011).
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Figure 1 The largely cancer specific 291-bp cfDNA amplicon in plasma
is inversely related to the presence of DTCs (qRT-PCR CK19:ABL X0.1%)
in the bone marrow of primary breast cancer patients on follow-up.
Comparison of (A) 96-bp cfDNA and (B) 291-bp cfDNA in patient
samples grouped by the presence or absence of DTCs (ICC and qRT-PCR)
and CTCs (CellSearch) in paired bone marrow aspirate and blood samples
from 64 primary breast cancer patients on follow-up. The box plots
show the median and inter-quartile ranges and the whiskers indicate
1.5 the inter-quartile range (*statistically significant, Mann–Whitney
non-parametric t-test).
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The fluctuations over time may be an important determinant,
along with combined investigations with DTCs and CTCs to
provide further information on the viability and metastatic
potential of these micrometastases.
Our data raise important questions regarding the issue of
dormancy in breast cancer. We and others have shown that rare
DTCs and CTCs can persist for many years after the end of breast
cancer treatment (Meng et al, 2004; Slade et al, 2005, 2009). As the
half-life of CTCs in the blood is estimated at 1–2 h (Meng et al,
2004), their presence may represent a dynamic balance between
proliferation from micrometastatic niches and cell death. This
turnover of residual cells is possibly one of the reasons why
cancer-derived cfDNA (above the apoptotic limit) persists in blood
for so long after diagnosis and treatment. A mathematical model of
breast cancer dormancy has recently been developed and
demonstrates that long-term breast cancer dormancy can be
maintained by a small subset of growth-restricted, dangerous
micrometastases (Willis et al, 2010). This theoretical model agrees
with the observations described herein of the persistence of a low
but steady number of CTCs and DTCs observed from growth-
restricted and not necessarily relapse-inducing micrometastases.
The additional measurement and molecular characterisation of
cfDNA derived from dying tumour cells may help to distinguish
these phases of dormancy.
In conclusion, the inverse correlation of DTCs (by CK19
qRT-PCR) in the bone marrow with the larger 291-bp amplicon
in cfDNA indicates that the dormancy period of breast cancer is
potentially characterised by two distinct phases: one in which
measures of viable DTCs are absent, during which measures of cell
death manifesting as cfDNA in the blood are evident, and
an alternate phase, characterised by evidence of viable DTCs, but
lower levels of cfDNA.
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